Perampanel as First Adjunctive Treatment in Patients with Focal-Onset Seizures in the FAME Study: Post hoc Analyses of Dose-Related Efficacy, Safety and Clinical Factors Associated with Response

BACKGROUND AND PURPOSE: Perampanel is approved for the adjunctive treatment of focal-onset seizures (FOS) with or without secondary generalized seizures. The FAME (Fycompa(®) as first Add-on to Monotherapy in patients with Epilepsy; NCT02726074) study evaluated the efficacy and safety of perampanel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong Wook, Kim, Ji Hyun, Lee, Sang Kun, Lee, Sang Ahm, Lee, Ji Woong, Kim, Min Young, Seo, Dae-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Epilepsy Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289380/
https://www.ncbi.nlm.nih.gov/pubmed/35910330
http://dx.doi.org/10.14581/jer.22002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289380/
https://www.ncbi.nlm.nih.gov/pubmed/35910330
http://dx.doi.org/10.14581/jer.22002

Ejemplares similares